To know the outcome of specially prepared blood derivative on treatment of decay of bone due to certain cancer medicines commonly termed as MRONJ (Medicine related osteonecrosis of jaw)
Not Applicable
Completed
- Conditions
- Health Condition 1: null- malignant disease and bony metastases receiving antiresorptives namely Zolendronate, Clorandonate, Palmidronate, Ebandronate and Denosumab
- Registration Number
- CTRI/2017/09/009615
- Lead Sponsor
- no
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 269
Inclusion Criteria
1.Patients referred to the dental services of TMH, receiving/ prior to receiving antiresorptives namely Zolendronate, Clorandonate, Palmidronate, Ebandronate and Denosumab
Exclusion Criteria
1.Patients who are referred to dental department but not receiving antiresorptive drugs.
2.Patients unwilling to give consent
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Osteonecrosis of Jaw <br/ ><br>2. Local and systemic factors predisposing osteonecrosis of jaw.Timepoint: Each three months upto 2 years from the date of enrollment.
- Secondary Outcome Measures
Name Time Method Pain, Infection, Pus discharge from jaw bones progressing to osteonecrosis of jawTimepoint: Each three months up to 2 years